SPECTACL: SPECTroscopic Assessment of Coronary Lipid

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2008

Conditions
Angina PectorisAngina, UnstableMyocardial Infarction
Interventions
DEVICE

Near Infrared Spectroscopy (NIRS) Imaging

Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.

DEVICE

intravascular ultrasound (IVUS)

Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.

Trial Locations (6)

10032

Columbia University Medical Center, New York

27705

Duke Medical Center, Durham

48073

William Beaumont Hospital, Royal Oak

02215

Beth Israel Deaconess Medical Center, Boston

01805

Lahey Clinic, Burlington

H1T 1C8

Montreal Heart Institute, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Infraredx

INDUSTRY

NCT00330928 - SPECTACL: SPECTroscopic Assessment of Coronary Lipid | Biotech Hunter | Biotech Hunter